Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Suffers Setback As Indian Patent Appeals Board Strikes Down Glivec Patent

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Hopes for Novartis to obtain a product patent for its chronic myeloid leukemia drug Gleevec (imatinib) were dashed after India's Intellectual Property Appellate Board ruled that Novartis' patent application covering the medicine's beta-crystalline version is not patentable because it failed to satisfy the requirements under Section 3(d) of the India Patents Act

You may also be interested in...



Novartis Says Adverse Gleevec Ruling Would Impact Outlook For India

As India’s Supreme Court prepares to deliver a landmark verdict next week on the patentability of Gleevec, Novartis prepares for stormy weather.

President Obama May Take Up IP Protection Issue During India Visit

MUMBAI - One of the top priorities for U.S. President Barack Obama during his four day visit to India may be to seek strengthened IP rights protection from the Indian government - a thorny issue that has kept some multinational companies away from committing R&D investments in the country despite availability of a large pool of scientists and significant cost advantages

President Obama May Take Up IP Protection Issue During India Visit

MUMBAI - One of the top priorities for U.S. President Barack Obama during his four day visit to India may be to seek strengthened IP rights protection from the Indian government - a thorny issue that has kept some multinational companies away from committing R&D investments in the country despite availability of a large pool of scientists and significant cost advantages

Related Content

UsernamePublicRestriction

Register

SC072365

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel